Publication details
Hepatitida C – možné průběhy onemocnění, význam terapie a dopady neléčené infekce
| Title in English | Hepatitis C – possible courses of the disease, importance of therapy and effects of untreated infection. |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Keywords | hepatitis C; epidemiology of hepatitis C; treatment of hepatitis C; direct-acting antivirals (DAAs) |
| Description | There are an estimated 70-80 million people living with chronic hepatitis C virus (HCV) infection worldwide. HCV is transmitted via the parenteral route. Before the introduction of routine testing of blood donors (in the Czech Republic in 1992), most people were infected through blood transfusions or blood derivatives. This route of transmission has lost importance in developed countries. The most at risk group is now clearly intravenous drug users, who share syringes, needles and other instrumentation needed to inject the drug. According to the 2020 EASL guidelines, treatment with directacting antivirals (DAAs) must be offered without delay to all persons with recently acquired and chronic HCV infection. The primary goal of treatment for chronic HCV is to cure the infection, i.e. to achieve a sustained virological response (SVR) defined as undetectable HCV RNA in peripheral blood 12 or 24 weeks after the end of antiviral treatment. Regimens using DAAs eliminate the serious adverse effects of pegylated interferon-? and ribavirin (which have been used in the past), have virtually no contraindications, treatment-related adverse effects are minimal, and treatment efficacy approaches 100%. |